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Abstract
Background: Treatment of hepatitis C (HCV) is very effective, achieving a cure in 50–90% of patients. Besides its own good
for individuals, this most likely translates in reduced transmission, but this phenomenon has yet to be fully explored.
Methods and Findings: In this mathematical modeling study done in the context of Vietnam, we estimated the public
health benefit that HCV therapy for injecting drug users (IDUs) may achieve. Treatment coverage of 25, 50 and 75% of
chronically HCV-infected IDUs (4 years into infection) is predicted to reduce the chronic HCV viremia prevalence respectively
by 21, 37 and 50%, 11 years after full scale up to the intended coverage. At a constant 50% coverage level, earlier treatment,
3, 2, and 1 year into infection is predicted to reduce the chronic HCV viremia prevalence by 46, 60 and 85%. In these later 3
scenarios, for every 100 treatment courses provided, a total of respectively 50, 61 and 94 new infections could be averted.
These benefits were projected in the context of current low coverage of methadone maintenance therapy and needles/
syringes exchange programs, and these services expansion showed complementary preventive benefits to HCV therapy.
The program treatment commitment associated with the various scenarios is deemed reasonable. Our model projections
are robust under adjustment for uncertainty in the model parameter values.
Conclusions: In this case study in Vietnam, we project that treatment of HCV for injecting drug users will have a preventative
herd effect in addition to curing patients in need for therapy, achieving a substantial reduction in HCV transmission and
prevalence.
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Introduction
It is estimated that 130–170 million people around the world
are chronically infected with the Hepatitis C Virus (HCV) [1].
HCV therapy is very effective, with 50–90% (depending on the
virus genotype and epidemiological context) of people receiving
the currently recommended regimen achieving a Sustained
Virological Response (SVR), considered a cure of the infection
[2–4]. HCV treatment is still prohibitively expensive and
considered complex, and like HIV therapy 10 years ago, it is
routinely offered in rich settings but almost entirely inaccessible in
resource-limited settings. We propose that lessons learned on the
HIV front be applied to overcome barriers to accessing HCV
therapy in developing countries. One recent observation with HIV
is that therapy, besides its own good for patients, is a potent
prevention method that markedly reduces transmission [5]. With
HCV, early mathematical modeling has now shown that
treatment may also reduce transmission and result in HCV
prevalence reduction [6,7]. The available data though only derive
from western contexts. Here, mathematical modeling was used in
a case study in Vietnam to estimate the preventive effect that HCV
therapy may have in a developing country context. This study
focuses on the injecting-drug-users (IDU) sub-population, who
carries the highest HCV burden. Although we appreciate that
caring for IDUs presents particular challenges, we emphasize that
evidence supports that compliance with therapy can be adequate
in drug users [8], that similar treatment success rates can be
observed in drug users and non-drug users [9], and importantly,
that HCV reinfection after successful treatment of IDUs may be
low [10–12].
Methods
The model
The compartmental deterministic model, shown in Figure 1,
considers the following groups of individuals: Susceptible (S)
individuals who inject drugs but have not yet acquired HCV.
Those who acquire infection are divided into acute asymptomatic
(AA) and acute symptomatic cases (AS). Both subgroups may
spontaneously clear infection/recover (R), or develop chronic
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acute symptomatic and chronic cases that will receive treatment.
Both may either respond to treatment and recover from infection
(R), or fail therapy and evolve/remain with chronic infection (C).
Finally, cases that spontaneously cleared infection or were cured
with treatment may be re-infected and re-enter the acute
asymptomatic or symptomatic infection compartments.
The model includes the effect of Methadone Maintenance
Therapy (MMT) and Needle-Syringe Exchange (NSE) programs.
The IDUs are separated between those who respectively access,
and do not access MMT, and movement takes place between the 2
sub-groups. In contrast, the NSE programs effect (nseeffect) are built
into the model equations of force of infection. (Table 1)
The intervention of key interest, HCV therapy, is only
considered for acute symptomatic cases (TA, who have fair
chances to present to or be reached by health services) and patients
with chronic disease (TC). Acute asymptomatic cases are not
considered for treatment due to the difficulty of reaching this
group and the short duration of this state. Retreatment in those
who failed therapy is not an option in this model (assuming a low
probability that it would be offered in the programmatic
conditions of interest), but it is possible for those re-infected after
successful treatment, as they re-enter the pool of susceptible
individuals. In a conservative manner, patients on treatment are
considered infectious over the duration of therapy given that only
a little over half achieve a complete Early Virological Response,
i.e. an undetectable viral load by 12 weeks on treatment [13].
Interventions scenarios
We studied 3 main intervention scenarios. In scenario A, we
introduced HCV therapy at various coverage levels - 25, 50 and
75% - for individuals who have been infected for an average of 4
years (see parameters estimates). In scenario B, treatment coverage
is fixed at 50%, but therapy is offered at increasingly early time
points into chronic infection (4, 3, 2 and 1 year). It also then
includes treatment of individuals with acute symptomatic infection
at a 75% coverage level. Both scenarios are built in the context of
current reach of MMT and NSE services, introduced in the model
in 2007. In Vietnam, NSE services were introduced and expanded
from 2005, and coverage has been roughly stable since 2007 [14].
MMT services appeared later with pilot projects started in 2008/
9, and they have so far achieved very modest coverage [15]. The
scenario C models an HCV therapy program covering 50% of
individuals reached 2.5 years into chronic infection, in combina-
tion with expanded NSE and MMT services. In all scenarios,
HCV therapy is introduced in 2012, but the selected coverage is
only achieved after a scale up period of 4 years (see model
equations), to mimic programmatic conditions. Likewise, expan-
sion of NSE and MMT services in scenario C is modeled with
a similar scale up period corresponding to national MMT services
expansion plans [16].
Outcomes
Conventionally, we first examined the effect of the interventions
on the prevalence of hepatitis C infection. Although this logically
included the prevalence of anti-HCV antibodies, we were here
primarily concerned with the prevalence of true chronic viremic
infections. Importantly, we also report the number of new
infections averted per 100 treatment courses provided. For each
scenario the model was run with and without treatment and the
predicted cumulative number of cases and treatments were
recorded. The number of cases averted was defined as the
cumulative number of cases predicted from the model run without
treatment minus the cumulative number of cases predicted from
the model run with treatment. The number of cases averted per
100 treatment courses was defined as 100 multiplied by the
Figure 1. Model schematic. S: Susceptible individuals; AA: Acute asymptomatic cases; AS: Acute symptomatic cases; TA: Treated Acute
symptomatic cases; R: Recovered infections; C: Chronic infections; TC: Treated Chronic infections.
doi:10.1371/journal.pone.0034548.g001
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number of treatments predicted from the model run with
treatment. The outcomes are examined up to only 2027, 15 years
after treatment introduction and only 11 years after full scale up,
to reflect a perspective directly appreciable by program and policy
makers.
Variables and Parameters Estimates
In Table 2, the variables/parameters point estimates derive
from the best current available evidence, and are used to run the
core simulations. When relevant, the ranges of parameter values
are used to run sensitivity analysis (see sensitivity analysis).
– hin and hout represent respectively the influx of new IDUs into
the S compartment and the IDUs leaving any compartment as
a result of death or injecting cessation. Although no published
data could be found, experts in Vietnam estimate that the IDU
population may have increased at an annual rate lower than
1% since 1990 (Quoc, Nguyen - FHI360, personnel commu-
nication). Therefore, hin and hout were set equal to maintain
a constant population size in the core model, and varied in the
sensitivity analysis. The hout estimate corresponds to an
injecting career length of 5.9 years, the average observed in
IDUs in a large Integrated Biological and Behavioral
Surveillance survey conducted in 10 provinces in Vietnam in
2009 (publication pending). Although some accounts, in other
settings, have reported longer heroin use careers, some mixed
non-injecting and injecting routes [17–19]. The Vietnam 2009
survey observed a total heroin use career of 7.9 years, and the
apparent time lag between heroin initiation and injecting in
this survey closely resembles that of another description [20].
hin and hout were also fitted simultaneously with b and l0 and
lM to reproduce the reported plateau HCV prevalence.
– b, the transmission coefficient, was fitted to reproduce the
HCV prevalence of 70–74% observed in IDUs in Vietnam
between 2003–2006 [21,22]. The resulting estimate infers
a force of infection l0=0.43, which corresponds to a time
between injecting onset to seroconversion of 2.3 years. It is
believed to fit well the context. Indeed, although some studies
from western settings have reported times from injecting onset
to HCV infection of around 3.3 years [23,24], a specific study
in Vietnam oriented towards young injectors reported a time to
seroconversion of 1.2 years [21].
– a, is a reduced injecting rate coefficient among those on MMT,
derived from findings in pilot MMT services where 21.6% on
MMT tested positive for opioids [25]. We further consider that
injecting in these individuals is reduced.
– m1 represents the baseline recruitment rate into the MMT
program, and corresponds to 1.3% of IDUs being reached by
this service in 2010 [15].
– m1new is the expanded recruitment into MMT, based on the
Vietnamese MOH objective of reaching 53% IDUs by 2015
[16].
– m2 is the drop-out from MMT observed in the pilot program in
Hai Phong and Ho Chi Minh city [25].
– nse represents the baseline NSE program achievements, and
incorporates that in 2007 and 2009, with 50 needles
distributed/IDU/year, only 10% of the IDUs’ need for clean
materials were covered in places where programs have been
established [14].
– nsenew is the expanded NSE program achievement used in
Scenario C, corresponding to an ambitious coverage of 100%
of IDUs with 250 needles/IDU/year, a figure lower than the
real estimated needs, but above a usual program target of 200
needles/person/year.
– durTA and durTC represent the length of therapy for patients with
respectively acute (24 weeks, conservative choice) and chronic
HCV infection [26]. Although treatment duration varies in
chronic infection for different genotypes (24–48 weeks), the
Table 1. Model Equations.
Core Model Equations
Individuals not on Methadone Maintenance Therapy
S09=hinP2l0S02houtS02m1S0+m2SM
AA09=(12q)l0(S0+nR0)2((1/durA)+hout)AA02m1AA0+m2AAM
AS09=ql0(S0+nR0)2((1/durA)+(covAS/waitAS)+hout)AS02m1AS0+m2ASM
C09=(12pCA)(1/durA)AA0+(12pCS)(1/durA)AS0+(12pRA)(1/durTA)TA0+(12pRC)(1/durTC)TC02((covC/waitC)+hout)C02m1C0+m2CM
TA09=(c ovAS/waitAS)AS02((1/durTA)+hout)TA02m1TA0+m2TAM
TC09=(c ovC/waitC)C02((1/durTC)+hout)TC02m1TC0+m2TCM
R09=p CS(1/durA)AS0+pCA(1/durA)AA0+pRC(1/durTC)TC0+pRA(1/durTA)TA02nl0R02houtR02m1R0+m2RM
And: l0=b(12nseeffect)(AA0+AS0+C0+AAM+ASM+CM)/P
Individuals on Methadone Maintenance Therapy
SM9=2lMSM2houtSM+m1S02m2SM
AAM9=(12q)lM(SM+nRM)2((1/durA)+hout)AAM+m1AA02m2AAM
ASM9=qlM(SM+nRM)2((1/durA)+(covAS/waitAS)+hout)ASM+m1AS02m2ASM
CM9=(12pCA)(1/durA)AAM+(12pCS)(1/durA)ASM+(12pRA)(1/durTA)TAM+(12pRC)(1/durTC)TCM2((covC/waitC)+hout)C0+m1C02m2CM
TAM9=(c ovAS/waitAS)ASM2((1/durTA)+hout)TAM+m1TA02m2TAM
TCM9=(c ovC/waitC)CM2((1/durTC)+hout)TCM+m1TC02m2TCM
RM9=p CS(1/durA)ASM+pCA(1/durA)AAM+pRC(1/durTC)TCM+pRA(1/durTA)TAM2nlMRM2houtRM+m1R02m2RM
And: lM=ab(12nseeffect)(AA0+AS0+C0+AAM+ASM+CM)/P
doi:10.1371/journal.pone.0034548.t001
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case mix expected in the population of interest [4].
– pRC is the overall sustained virological response (SVR) expected
in the population of interest with chronic infection. It stems first
from an estimated weighted average SVR (SVR=0.78)
expected for the case mix of prevalent genotypes in South-
East and East Asia in well controlled settings [4]. It further
considers a reduced efficacy fraction that would likely apply in
programmatic conditions giving notably access to patients with
HIV co-infection (30% of IDUs in Vietnam, IBBS 2009-
publication pending). However, as recently reported in a meta-
analysis [9], we estimated that SVR is not significantly different
between IDUs (including active IDUs) and non-IDUs.
– pRA, the treatment-induced SVR expected among patients with
acute symptomatic infection, was also reduced from rates
reported in more controlled conditions (SVR=0.85) [27,28].
– n is the reduced ratio of HCV acquisition expected in
individuals who previously cleared infection (in response to
therapy or spontaneously), as opposed to individuals without
prior infection. It is derived from several small cohort studies
which evidenced reinfection rates of 5% per annuum or less in
IDUs successfully treated for HCV [10–12] and reduced
chronic infection re-establishment following previous sponta-
neous clearance [29].
– waitC, the duration of infection before individuals with chronic
HCV are treated, is based in Scenario A on an injecting career
length when IDUs are reached and delay to seroconversion of
respectively 6 and 2 years.
Sensitivity Analysis
In both intervention scenarios A and B, we reexamined the
model outputs after applying the estimated lower and upper values
of all relevant parameters (Table 2). When available, published
evidence was used. Otherwise, programmatically driven or
arbitrary (+/215%) variations were applied. A univariate extreme
value sensitivity analysis was perfomed.
Results
Increasing coverage
Before interventions are introduced, the model accurately
reproduced the HCV antibody endemic prevalence of around
72% reported in IDUs in Vietnam between 2003 and 2006.
Modelling the introduction in 2007 of MMT and NSE programs
Table 2. Variables and Parameters Estimates.
Symbol Parameter description Estimate Range in SA Approach
hin Recruitment rate of susceptible IDUs 0.17/y 0.145–0.196 +/215%
hout Exit rate (death and cessation) 0.17/y 0.145–0.196 +/215%
b Transmission coefficient 0.73 0.35–1.97*
l0 Force of infection in IDUs not on MMT 0.43 0.11–1.52**
lM Force of infection in IDUs on MMT 0.043 0.011–0.152**
BL prev Baseline HCV antibody prevalence 72 41–90* [33]
a Reduced injecting coefficient in IDUs on MMT 0.1 0.085–0.115 +/215%
m1 Baseline rate of recruitment into the MMT program 0.003 0.0025–0.0035 +/215%
m1new Expanded rate of recruitment into the MMT program 0.123 N/A
m2 Rate of drop-out from MMT 0.14/y 0.119–0.161 +/215%
nse Baseline proportion of IDUs covered with sufficient clean injecting materials 0.1 0.085–0.115 +/215%
nsenew Expanded proportion of IDUs covered with sufficient clean injecting materials 0.5 N/A
q Proportion of acute symptomatic infections 0.20 0.15–0.25 [34,35]
durA Duration of acute HCV infection 0.5 y N/A [34]
pCA Proportion of spontaneous clearance in acute asymptomatic infections 0.18 0.13–0.24 [36]
pCS Proportion of spontaneous clearance in acute symptomatic infections 0.31 0.26–0.36 [36]
durTA Treatment regimen duration for acute cases 24 wks N/A [26]
durTC Treatment regimen duration for chronic case 48 wks 24–72 [26]
pRC Proportion of treated chronic cases that recover 0.65 0.55–0.73 [4]
pRA Proportion of treated acute symptomatic cases that recover 0.75 N/A [27,28]
n Reduced re-infection ratio in people with prior virus clearance 0.05 0.006–0.19 [10]
CovC Treatment coverage for chronic cases 25, 50, 75% N/A
CovAS Treatment coverage for acute symptomatic cases 75% N/A
waitC Length of infection before therapy in chronically infected cases 1–4 y .–8 [18,19]
waitAS Length of infection before therapy in acutely infected cases 12 wks N/A
tT Duration for full HCV therapy scale up 4 y .–8
tN Duration for full MMT and NSE scale up 4 y N/A
*b range selected to obtain the published range of baseline HCV Ab prevalence.
**l0 and lM vary with b.
doi:10.1371/journal.pone.0034548.t002
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(Fig. 2) No field observation is available to confirm this trend, but
it is known that the HIV prevalence in IDUs has started to decline
in Vietnam since 2005 and the start of harm reduction
interventions [16]. Modelling the introduction and scale up of
HCV therapy from 2012 predicts a very noticeable HCV
prevalence reduction. The effect on the antibody prevalence
appears smaller than that for chronic HCV viremia, as people
cured from infection remain antibody positive. Increasing
coverage levels predicted incremental benefits, such that by 2027
(11 years after full scale up), the 25, 50 and 75% coverage predict
respectively a reduction of chronic HCV viremia prevalence of 21,
37 and 50%. Of importance, we project that at these respective
coverage levels, every 100 treatment courses would prevent 37, 45
and 53 new infections, in addition to curing the 65% of patients
offered treatment. This unique quantitative perspective has direct
programmatic implications, especially with regard to cost-
effectiveness.
Treating earlier
We further examined the impact of initiating treatment at an
earlier point into patients’ infection (Fig. 3). At a constant 50%
coverage level, earlier treatment had remarkable incremental
benefits. From the background 37% chronic viremia prevalence
reduction seen if treating patients 4 years into infection (equivalent
to scenario A), more proactive patient identification and
recruitment into treatment 3, 2 and 1 years after established
infection would result in a chronic viremia prevalence reduction of
respectively 46, 60 and 85% after 11 years of fully scaled
intervention. This illustrates the high number of transmitted
infections that occur in every year of injection sharing. Eventually,
the addition of an ambitious approach to identify and treat 75% of
acutely infected symptomatic cases offers insignificant additional
benefits, which is of no surprise considering the marginal time
advantage, and the small proportion that acute symptomatic
patients represent in the total case population. Predicted cases
averted increase rapidly up to 94 averted infections per 100
treatments if treating patients 1 year into established infection. As
an extension, we found that even at low coverage (25%), very early
treatment (1 year) has important effects, reducing chronic viremia
prevalence by 60% and averting 61 new infections per every 100
treatments (graph not shown).
Combining treatment with expanded harm reduction
programs
In Scenario C, starting HCV therapy to cover 50% of the IDUs
2.5 years into established disease offers a chronic HCV viremia
reduction of 52%. The addition of expanded MMT services brings
an additional prevalence reduction of 13% (down by 65%), and
finally, expansion of NSE services adds a further 20% effect,
bringing the chronic HCV viremia prevalence down to 9% after
11 years of full implementation (a total reduction effect of 85%).
However, the addition of expanded MMT and NSE services does
not greatly modify the number of infections averted per 100
treatment courses.
Program commitment
We further projected that for every 1000 IDUs (our total model
baseline population), a coverage of 75% of cases 4 years into
infection (viremia prevalence reduction of 50%) corresponds to
a cumulative number of 723 patients treated after 15 years of
implementation. Intervening early (1 year) with 50% coverage
(prevalence reduction of 85%) corresponds in turn to a cumulative
treatment caseload of 947 patients after 15 years. On an average
yearly basis, these 2 situations correspond respectively to 48 and
63 patients treated per year, for every 1000 IDUs. If extrapolating
to the example situation of Hanoi (estimated IDU population in
2008=38,000 people [14]) these scenarios would correspond to
treating respectively a total of 1824 and 2394 patients per year in
the city.
Sensitivity analysis
The sensitivity analyses showed our model predictions to be
qualitatively robust. Effects observed were consistent in scenario A
and B (Table 3, effects in scenario A only are presented). The
outputs were virtually unaffected by the applied changes to a, m1,
m2, nse, q, pCA, pCS and durTC. A doubling of the intervention scale up
duration (tT) only marginally reduced benefits and the applied
reduced rate in treatment response (pRC) had also little effect. As
the applied lower and upper range of pRC correspond in turn to the
SVR that may be expected in programmatic conditions for
a subpopulation of patients infected with respectively genotype 1
or genotype 2–3, we project that the preventive effect of treatment
may not be greatly modified in a program that would selectively
target patients with more favorable genotypes. Importantly, the
high estimate rate of reinfection (n), corresponding to 100% re-
infection after a little over 5 years, showed also very discrete
reduction of the preventive benefits, as our model allowed
treatment in case of reinfection. Outputs were more sensitive to
variations in recruitment and exit rates, but a population increase
with a higher influx of IDUs (which may more likely be happening
in Vietnam according to experts) showed a noticeable increase in
the projected prevalence reduction. Interestingly though, the later
and new infections averted per 100 treatments changed in opposite
direction with variation of hin and hout, as for example, a population
increase would ‘‘dilute’’ prevalent cases and reduce the relative
contribution of treatment on averted infections. Also, changes in
the baseline HCV Ab prevalence influenced the model outputs,
showing higher treatment preventive benefits at lower endemic
levels, and yet a remaining 34% drop in chronic viremia
prevalence in the extreme situation of a 90% baseline Ab
prevalence. Finally, a doubling of the estimated time into infection
before treatment (scenario A only) showed a noticeable reduction
of treatment effect, yet with a persisting reduction of chronic
viremia prevalence of 30%.
Discussion
Main Findings
In this study, we confirm previous predictions [6,7] that
treatment of chronic hepatitis C in injecting drug users may
substantially reduce transmission of the virus and reduce
prevalence. To our knowledge, ours is the first application in
a developing country context, Vietnam in this circumstance. We
found that even at low coverage levels (25%), HCV therapy results
Figure 2. Projected preventive effect of increasing hepatitis C treatment coverage (Scenario A). Panel A): Reduction of anti-HCV
antibody prevalence following treatment introduction and scale up to a 25%, 50% and 75% coverage level. Panel B): Reduction of prevalence of HCV
true viremic chronic infections. Panel C): new infections averted per every 100 treatment courses of chronically infected cases.
doi:10.1371/journal.pone.0034548.g002
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infection, and that more ambitious treatment programs could
achieve a chronic viremia prevalence reduction of up to 85% after
only 15 years of initiation and 11 years of full scale up. We show in
particular that pro-active efforts to detect and treat patients early
into infection offer rapidly increasing prevention benefits, owing to
the high number of transmitting events that occur each year of
injection sharing. We demonstrated these effects in the context of
low coverage with harm reduction interventions (MMT and NSE),
as currently observed in Vietnam, and show that expansion of
these services would offer additive preventive benefits to an HCV
treatment program.
Implications
Worldwide, 130–170 million individuals are chronically infected
with HCV [1]. Effective therapy exists and yet, a minority of
patients in need (most live in developing countries) can access
therapy. Here, we stress that treatment is not only beneficial for
individual patients, and show that it is a plausible prevention
method. At present, harm reduction methods, with other benefits,
are considered the only option for controlling the spread of HCV
among injecting drug users. Yet, often, they are the object of great
controversy, domestically and among certain donors, and their
implementation is painfully slow [15]. We argue and have
provided new evidence that treatment of hepatitis C as prevention
must be appreciated as a potential new tool to control the spread
of this disease. We add, in due consideration of the current cost
barrier to increased treatment access, that the true cost-
effectiveness of this intervention must factor in its preventive
effect. We showed in one treatment scenario that for every 100
patients started on treatment (of whom we expect 65% would be
cured), 94 new infections could be averted. In gross terms, this
would mean that the cost per treatment and per person should be
halved, as each treatment would be expected to prevent roughly
one additional infection.
Strengths and limitations
Our sensitivity analyses, which included the application of
extreme values to some of the parameters, showed our model
outputs to be robust, and that the predicted HCV therapy
preventive effects could apply in a range of different contexts,
including within a wide range of baseline HCV prevalence, despite
high reinfection rates, or reduced treatment efficacy. We have
mimicked programmatic realities by building in a gradual scale up
of the interventions of interest, rather than considering their
introduction at a given instant as other modeling studies have
done. We also projected and discussed the effects of the
interventions at a perspective of 15 years post initiation and 11
years post full scale up, which may be of greater relevance to
policy makers than a longer time horizon which would lead to
predictions of greater effects. The following limitations are noted.
Although we did not consider very unrealistic targets, such as
elimination, we appreciate that some of our scenarios represent
ambitious objectives. Many are skeptical of the feasibility of
treating HCV-infected IDUs with ongoing substance use, despite
published evidence that active IDUs can indeed be treated
successfully [8,9]. We recognize that successful programs require
particular efforts and multidisciplinary interventions. Such care at
a coverage level of 50% may prove very challenging, in particular
in resource-limited settings. In turn, innovative interventions at the
community level and using peers have helped filling some support
gaps that may be unavailable in the institutional health sector [30].
In addition, we showed that even high treatment coverage in our
models correspond to a manageable treatment caseload (financial
Figure 3. Projected preventive effect of treating earlier into infection (Scenario B). Panel A): Reduction of anti-HCV antibody prevalence
following treatment of 50% of chronically infected cases, 4, 3, 2 and 1 year into infection, and 75% of acute symptomatic cases. Panel B): effect on
chronic HCV viremia prevalence. Panel C): new infections averted per every 100 treatment courses initiated.
doi:10.1371/journal.pone.0034548.g003
Table 3. Model outputs changes in sensitivity analyses.
Scenario A (75% coverage, 4 years into infection)
Parameter
Chronic viremia
prevalence reduction
New infections
averted/100 treatments
Chronic viremia
prevalence reduction
New infections
averted/100 treatments
Reference effect 50% 53 50% 53
Parameter Low Estimate High Estimate
hin 41% 62 60% 45
hout 63% 36 40% 74
BL Ab prev 68% 96 34% 11
a, m1, m2, nse 50% 53 50% 53
Q 50% 52 50% 54
pCA 49% 48 52% 60
pCS 50% 52 50% 54
durTC 52% 49 49% 56
pRC 45% 44 54% 60
n 51% 56 47% 43
waitC N/A N/A 30% 41
tT N/A N/A 48% 47
doi:10.1371/journal.pone.0034548.t003
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highlight that at low coverage level, although treatment would not
greatly reduce prevalence, it would avert a substantial number of
infections for every 100 treatment courses offered. Another
limitation of our study is that it considered the integration of
HCV therapy, MMT and NSE at the population level, rather than
at the point of individual care. That is we do not model the
mechanism of an HCV treatment program offering MMT and
sufficient clean injecting materials to all treated subjects. However,
the reality of services integration, as it is known with other
compartments of care such as this of HIV and TB care, is
complex. The implementation of MMT and NSE services is again
often a sensitive matter, calling upon complex inter-sectorial
engagement. As a result, we considered that the integration of
HCV therapy, MMT and NSE services would realistically rely on
referral between programs, and that complementarity would best
be examined at the population level. As a next limitation, we did
not consider the effect that changing prevalence of HIV or
Hepatitis B co-infection could have on the risks of HCV
acquisition or transmission. While our model was fitted to
reproduce the HCV prevalence observed in IDUs at a time of
30% HIV co-infection, it is possible that this level of co-infection
will vary over the coming 15 years, with a resulting effect that is
not factored into this analysis. Then, although it is discussed that
‘‘susceptible’’ IDUs with recent onset on injecting have a different
risk of HCV acquisition than more ‘‘experienced’’ injectors, we
did not distinguish the 2 groups, as their distinct risks have not yet
been well quantified [31]. Finally, we left out the risk of sexual
transmission of HCV from IDUs, and only appreciate that we
ignored a small (uncertain) number of infections averted to other
groups. Acknowledging these limitations, we remain confident that
they would not significantly alter the effects described in this study.
Evidence from other studies
After projecting preventive benefits of HCV therapy in IDUs in
the United Kingdom [6], Martin et al. used the optimal control
theory to determine what the optimal HCV treatment programme
strategy would be under a variety of policy objectives and budget
constraints. They projected that an immediate programme of
maximum intensity designed to minimize prevalence, HCV health
utility loss and health services costs (which we extrapolate most
closely matches our approach) would achieve greater cost-
effectiveness, as opposed to programmes with notably delayed
implementation addressing more restricted policy objectives or
finite prevalence reduction targets [32]. In their study of optimal
treatment allocation, Zeiler et al. determined that, as far as
maximizing prevention benefits is concerned, HCV treatment
should predominantly be allocated to IDUs not enrolled in MMT,
as opposed to IDUs in MMT [7]. We stress that the concept of
treatment allocation to optimize prevention benefits raises of
course ethical dilemmas. In the present study, we introduce the
important concept of timing of treatment, and project that the
potential preventive benefits of HCV therapy are optimized if
gains are made to treat patients earlier into their disease, or that at
equal coverage, greater prevention effects are achieved if treating
patients earlier into the infection.
Further work
It is now needed to confirm and quantify in real-life the
preventive effects of HCV therapy projected in this and other
mathematical modeling studies. Similarly, it will be important to
further study the cost-effectiveness of HCV therapy in developing
countries with due appreciation of its direct benefits to patients
and its indirect benefits to the population.
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